📊 APUS Key Takeaways
Is Apimeds Pharmaceuticals US, Inc. (APUS) a Good Investment?
Apimeds is a pre-revenue pharmaceutical company with severe cash burn and negative profitability. The company is hemorrhaging cash at -$5.1M operating cash flow with only $7.0M in reserves, creating critical runway concerns. Without demonstrated commercial traction or clear path to profitability, the company faces existential funding risk.
Apimeds Pharmaceuticals US appears to be a pre-revenue pharmaceutical company with no demonstrated commercial operating base, negative operating cash flow, and recurring losses that remain large relative to its asset base. The balance sheet is currently clean, with high liquidity, substantial cash relative to liabilities, and no meaningful leverage, but the business is still fundamentally dependent on turning R&D and development activity into eventual revenue before cash burn materially erodes that cushion.
Why Buy Apimeds Pharmaceuticals US, Inc. Stock? APUS Key Strengths
- Strong current ratio of 8.34x provides near-term liquidity buffer
- Zero debt burden eliminates solvency pressure from leverage
- Stockholders equity of $8.2M provides some balance sheet cushion
- Very strong liquidity profile with a current and quick ratio of 8.34x
- Low financial risk today due to minimal liabilities and effectively no long-term debt
- Cash of $6.99M provides a near-term operating runway relative to current obligations
APUS Stock Risks: Apimeds Pharmaceuticals US, Inc. Investment Risks
- Pre-revenue model with no commercial product sales indicates zero market validation
- Operating cash burn of -$5.1M with only ~1.4 years of cash runway at current burn rate
- Negative ROE of -59.4% and ROA of -52.4% indicate severe value destruction
- No insider trading activity in 90 days suggests lack of insider confidence
- Development-stage pharmaceutical with unproven product-market fit and regulatory approval uncertainty
- No reported revenue or gross profit indicates unproven commercialization and weak growth quality
- Operating cash outflow of $5.11M and free cash flow of -$5.14M imply ongoing cash burn
- Negative ROE of -59.4% and ROA of -52.4% show poor capital efficiency and sustained unprofitability
Key Metrics to Watch
- Monthly cash burn rate and runway duration
- Progress toward revenue generation or regulatory milestones
- Changes in operating cash flow trajectory
- Debt issuance or equity dilution financing activity
- Clinical trial progress and FDA approval status
- Quarterly operating cash burn versus cash balance
- Any emergence of revenue and improvement in operating loss trend
Apimeds Pharmaceuticals US, Inc. (APUS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.34x current ratio provides a solid financial cushion.
APUS Profit Margin, ROE & Profitability Analysis
APUS vs Healthcare Sector: How Apimeds Pharmaceuticals US, Inc. Compares
How Apimeds Pharmaceuticals US, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Apimeds Pharmaceuticals US, Inc. Stock Overvalued? APUS Valuation Analysis 2026
Based on fundamental analysis, Apimeds Pharmaceuticals US, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Apimeds Pharmaceuticals US, Inc. Balance Sheet: APUS Debt, Cash & Liquidity
APUS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Apimeds Pharmaceuticals US, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.17 indicates the company is currently unprofitable.
APUS Revenue Growth, EPS Growth & YoY Performance
Apimeds Pharmaceuticals US, Inc. Dividends, Buybacks & Capital Allocation
APUS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Apimeds Pharmaceuticals US, Inc. (CIK: 0001894525)
📋 Recent SEC Filings
❓ Frequently Asked Questions about APUS
What is the AI rating for APUS?
Apimeds Pharmaceuticals US, Inc. (APUS) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are APUS's key strengths?
Claude: Strong current ratio of 8.34x provides near-term liquidity buffer. Zero debt burden eliminates solvency pressure from leverage. ChatGPT: Very strong liquidity profile with a current and quick ratio of 8.34x. Low financial risk today due to minimal liabilities and effectively no long-term debt.
What are the risks of investing in APUS?
Claude: Pre-revenue model with no commercial product sales indicates zero market validation. Operating cash burn of -$5.1M with only ~1.4 years of cash runway at current burn rate. ChatGPT: No reported revenue or gross profit indicates unproven commercialization and weak growth quality. Operating cash outflow of $5.11M and free cash flow of -$5.14M imply ongoing cash burn.
What is APUS's revenue and growth?
Apimeds Pharmaceuticals US, Inc. reported revenue of N/A.
Does APUS pay dividends?
Apimeds Pharmaceuticals US, Inc. does not currently pay dividends.
Where can I find APUS SEC filings?
Official SEC filings for Apimeds Pharmaceuticals US, Inc. (CIK: 0001894525) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is APUS's EPS?
Apimeds Pharmaceuticals US, Inc. has a diluted EPS of $-0.47.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is APUS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Apimeds Pharmaceuticals US, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is APUS stock overvalued or undervalued?
Valuation metrics for APUS: ROE of -59.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy APUS stock in 2026?
Our dual AI analysis gives Apimeds Pharmaceuticals US, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is APUS's free cash flow?
Apimeds Pharmaceuticals US, Inc.'s operating cash flow is $-5.1M, with capital expenditures of $35.9K.
How does APUS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -59.4% (avg: 15%), current ratio 8.34 (avg: 2).